Mohsin Bilal is Assistant Professor (Research) and a Data Scientist at the PathLAKE centre of excellence for AI in pathology at the Tissue Image Analytics Centre (TIACentre), University of Warwick, UK. A significant portion of his work focused on predictive modelling of molecular pathways and genetic alterations to discover distinct differential histology in colorectal cancer. Dr. Bilal has also worked as Assistant Professor in the Computer Science Department at Umm Al-Qura University in Saudi Arabia in the past. Dr. Bilal is currently working on developing cutting-edge AI solutions for cancer early diagnosis and personalised treatment, and digital pathology transformation in Pakistan. He has published several peer-reviewed articles related to machine learning, image processing, and computational pathology.
I started Histopathology training late in 2012, my main aim then was to
be competent enough to pass specialty exams and progress to the next level.
I completed my master’s degree in Pathology in 2017, and became a fellow of the Royal college of Pathologists in 2019. I am also an active member of several Pathology societies including the USCAP, the BDIAP and ESP. Additionally, I am an associate member of the Academy of Medical Educators and a board member of the Manchester Medical Society. I am also a peer reviewer for Cureus Journal.
My work experience includes Histopathology reporting, with a subspeciality interest in breast and GI Pathology, postgraduate and undergraduate teaching.
I am a strong advocate of digital Pathology and cautiously optimistic about the use of artificial intelligence in Pathology. I also endorse social media engagement for pathologists to educate in, and propagate Histopathology, and I have found the power of sharing knowledge on Twitter and Linked in to be second to none; it is abundant, accessible, free, and high quality.
I experienced academia when completing my master’s degree, and, as an early career doctor, I am very interested in identifying and pursuing research opportunities.
I believe Histopathology is a profession that lies at the exciting crossroads of clinical care, cellular biology, genetics and digital technology, with a never-ending learning curve, that proves to be continuously challenging and thought provoking.
Dr Nikolay Burlutskiy is Director of Artificial Intelligence at AstraZeneca R&D, UK.
His interest is in applying AI methods, especially computer vision, to improve and accelerate drug development pipelines. Nikolay has background in computer science with a PhD in machine learning and deep learning. Prior to AstraZeneca, he was leading algorithm development of Inify, a successful decision support tool to empower pathologists, at ContextVision in Stockholm. He also worked as R&D AI engineer at Samsung Electronics in South Korea developing vacuum cleaning robots. He co-authored over 20 peer-reviewed publications including several US patents on AI applications.
Dr Krishna’s area of interest is lifelong, persistent viral infections; how these pathogens have evolved to remain in the host for life and how persistent infections affect the host’s health. This started with work on HIV at the University of Oxford, trying to understand how broadly neutralising antibodies could be used to treat the persistent virus that causes AIDS. He then pursued a PhD in human cytomegalovirus (HCMV, a member of the herpesvirus family) at the University of Cambridge. Here he showed that viral persistence could be treated with a first-of-its-kind, antiviral, fusion toxin protein. Dr Krishna then received a three year Fellowship to work at the Cleveland Clinic (Ohio, USA) on mechanisms of HCMV reactivation after stem cell transplant. Most recently, Dr Krishna has been studying Long COVID, which may be caused by persistent SARS-CoV-2 infections.